<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:32:02Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2394455" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2394455</identifier><datestamp>2009-09-10</datestamp><setSpec>brjcancer</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="letter">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2394455</article-id>
      <article-id pub-id-type="pmcid">PMC2394455</article-id>
      <article-id pub-id-type="pmc-uid">2394455</article-id>
      <article-id pub-id-type="pmid">14612909</article-id>
      <article-id pub-id-type="pii">6601371</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6601371</article-id>
      <article-id pub-id-type="pmid">14612909</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>BRAF</italic> mutations in non-Hodgkin's lymphoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J W</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoo</surname>
            <given-names>N J</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soung</surname>
            <given-names>Y H</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>H S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>W S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>S Y</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J H</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>J Y</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>Y G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>C J</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ko</surname>
            <given-names>Y H</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>S H</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nam</surname>
            <given-names>S W</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J Y</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>S H</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><sup>1</sup>Department of Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul 137-701, Korea</aff>
      <aff id="aff2"><label>2</label><sup>2</sup>Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul 135-710, Korea</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:suhulee@cmc.cuk.ac.kr">suhulee@cmc.cuk.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>11</month>
        <year>2003</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>17</day>
        <month>11</month>
        <year>2003</year>
      </pub-date>
      <volume>89</volume>
      <issue>10</issue>
      <fpage>1958</fpage>
      <lpage>1960</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>04</month>
          <year>2003</year>
        </date>
        <date date-type="rev-recd">
          <day>30</day>
          <month>07</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>09</month>
          <year>2003</year>
        </date>
      </history>
      <copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement>
      <copyright-year>2003</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <kwd-group>
        <kwd>mutation</kwd>
        <kwd>BRAF</kwd>
        <kwd>RAS</kwd>
        <kwd>non-Hodgkin's lymphoma</kwd>
        <kwd>oncogene</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>The activated RAS proteins excite the mitogen-activated protein (MAP) kinase pathway (RASâRAFâMEKâERKâMAP kinase pathway) by recruiting the cytosolic protein RAF (<xref ref-type="other" rid="bib5">Downward, 2003</xref>). <italic>RAF</italic> gene family consists of three members (<italic>ARAF1</italic>, <italic>BRAF</italic> and <italic>RAF1</italic>), each encoding serine/threonine kinases that are regulated by binding to RAS. RASâRAFâMEKâERKâMAP kinase pathway plays a critical role in cell proliferation, and is frequently activated in cancer cells. For example, approximately 10â20% of all human tumours contain mutated versions of RAS proteins (<xref ref-type="other" rid="bib2">Bos, 1989</xref>). Recently, <xref ref-type="other" rid="bib4">Davies <italic>et al</italic> (2002)</xref> identified somatic mutations of <italic>BRAF</italic> in 66% of malignant melanomas and at a lower frequency in a wide range of human cancers. So far, all <italic>BRAF</italic> mutations have been reported within two kinase domains (G-loop and activation segment domains), and the most common mutation is a single substitution, V599E (<xref ref-type="other" rid="bib3">Brose <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib4">Davies <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib8">Naoki <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib10">Rajagopalan <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib13">Yuen <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib9">Pollock <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib11">Satyamoorthy <italic>et al</italic>, 2003</xref>). Mutated BRAF proteins have elevated kinase activity and transforming activity in NIH3T3 cells (<xref ref-type="other" rid="bib4">Davies <italic>et al</italic>, 2002</xref>). Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation (<xref ref-type="other" rid="bib4">Davies <italic>et al</italic>, 2002</xref>). Several studies have reported a low incidence of <italic>Ras</italic> gene mutation in non-Hodgkin's lymphoma (NHL) (<xref ref-type="other" rid="bib1">Ahuja <italic>et al</italic>, 1990</xref>). Although screening of <italic>BRAF</italic> mutation in human tumours has widely been performed, to date the data on <italic>BRAF</italic> mutation in NHL tissues is lacking. In the present study, we investigated the occurrence of <italic>BRAF</italic> gene mutations in NHLs.</p>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <p>Paraffin-embedded tissues of human NHL were obtained from 164 patients. These samples were stained with haematoxylinâeosin, examined by immunohistology, and then classified according to the Revised European-American Lymphoma (REAL) classification (<xref ref-type="other" rid="bib6">Harris <italic>et al</italic>, 1994</xref>). The NHLs analysed consisted of seven B-cell small lymphocytic lymphomas, three mantle cell lymphomas, four follicular lymphomas, 49 mucosa-associated lymphoid tissue (MALT)-type lymphomas, 67 diffuse large B-cell lymphomas, four precursor T-lymphoblastic lymphomas, one T-cell chronic lymphocytic leukaemia, 14 peripheral T-cell lymphomas, unclassified, 14 angiocentric lymphomas, and one intestinal T-cell lymphoma. Ethical committee approval for the study was obtained. Through the microdissection technique, we selectively procured tumour cells and corresponding normal cells from histological sections of the 164 NHLs. Briefly, malignant cells were selectively procured from haematoxylin and eosin-stained sections using a 30G1/2 hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) affixed to a micromanipulator, as described previously (<xref ref-type="other" rid="bib7">Lee <italic>et al</italic>, 1998</xref>). We also microdissected normal cells and used them for corresponding normal DNA. This microdissection technique used in this study has been proved to be precise and effective for procurement of tumour cells without normal cell contamination (<xref ref-type="other" rid="bib7">Lee <italic>et al</italic>, 1998</xref>). DNA extraction was performed by a modified single-step DNA extraction method, as described previously (<xref ref-type="other" rid="bib7">Lee <italic>et al</italic>, 1998</xref>).</p>
      <p>Genomic DNA each from normal cells or tumour cells was amplified with two primer pairs covering exons 11 and 15 of <italic>BRAF</italic> gene, because all of the <italic>BRAF</italic> mutations have been so far detected in exons 11 and 15 that encode the kinase domains in G-loop and the activation segment of BRAF, respectively. Radioisotope was incorporated into the PCR products for detection by autoradiogram. The PCR reaction mixture was denatured for 1âmin at 94Â°C and incubated for 30 cycles. Other procedures of polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis were performed as described previously (<xref ref-type="other" rid="bib12">Shin <italic>et al</italic>, 1999</xref>). After SSCP, DNAs showing mobility shifts were cutout from the dried gel, and reamplified for 30 cycles using the same primer sets. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA) according to the manufacturer's recommendation.</p>
    </sec>
    <sec>
      <title>RESULTS</title>
      <p>SSCP analysis of <italic>BRAF</italic> identified four aberrant bands (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p><italic>BRAF</italic> gene mutations in NHLs. SSCP (<bold>A</bold>â<bold>C</bold>) and DNA sequencing analyses (<bold>D</bold>â<bold>F</bold>) of DNA from tumours (lane T) and normal tissues (lane N). Exon 11 (<bold>A</bold>, <bold>B</bold>) and exon 15 (<bold>C</bold>) of <italic>BRAF</italic> were amplified. SSCPs of DNA from the tumours show wild-type bands and additional aberrant bands (arrows) as compared to SSCP from normal cells from the same patients. (<bold>D</bold>) Sequencing analysis from the aberrant band in (<bold>A</bold>). There is a G to C transversion at nucleotide 1403 of <italic>BRAF</italic> (arrow) in tumour tissue as compared to normal tissue. (<bold>E</bold>) Sequencing analysis from the aberrant band in (<bold>B</bold>). There is a G to C transversion at nucleotide 1402 of <italic>BRAF</italic> (arrow) in tumour tissue as compared to normal tissue. (<bold>F</bold>) Sequencing analysis from the aberrant band in (<bold>C</bold>). There is an A to G transition at nucleotide 1778 of <italic>BRAF</italic> (arrow) in tumour tissue as compared to normal tissue. Numbering of cDNA of <italic>BRAF</italic> was made in respect to the ATG start codon (GenBank).</p></caption><graphic mime-subtype="jpeg" xlink:href="89-6601371f1"/></fig>). Enrichment and DNA sequence analysis of these aberrantly migrating bands led to the identification of four <italic>BRAF</italic> mutations (2.4%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). All of the four <italic>BRAF</italic> mutations were observed in diffuse large B-cell lymphomas (6.0% of the 67 cases). Although <italic>BRAF</italic> mutations were detected only in diffuse large B-cell lymphomas, this relationship was not statistically significant (<italic>P</italic>&gt;0.05). Three of the four <italic>BRAF</italic> mutations involved codon 468 (two G468R and one G468A) in the G-loop domain, and the remaining one was found at codon 593 (D593G) in the activation segment domain (<xref rid="tbl1" ref-type="table">Table 1</xref><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Summary of <italic>BRAF</italic> mutations identified in the NHLs</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th colspan="2" align="left" valign="top" charoff="50"><bold>BRAF mutations</bold><hr/></th><th align="left" valign="top" charoff="50">Â </th><th align="left" valign="top" charoff="50">Â </th></tr><tr><th align="left" valign="top" charoff="50"><bold>Nucleotide</bold></th><th align="left" valign="top" charoff="50"><bold>Amino acids</bold></th><th align="left" valign="top" charoff="50"><bold>Anatomical site</bold></th><th align="left" valign="top" charoff="50"><bold>Histologic type</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">G1403C</td><td align="left" valign="top" charoff="50">G468A</td><td align="left" valign="top" charoff="50">Cervical lymph node</td><td align="left" valign="top" charoff="50">Diffuse large B-cell lymphoma</td></tr><tr><td align="left" valign="top" charoff="50">G1403C</td><td align="left" valign="top" charoff="50">G468A</td><td align="left" valign="top" charoff="50">Cervical lymph node</td><td align="left" valign="top" charoff="50">Diffuse large B-cell lymphoma</td></tr><tr><td align="left" valign="top" charoff="50">G1402C</td><td align="left" valign="top" charoff="50">G468R</td><td align="left" valign="top" charoff="50">Tongue mucosa</td><td align="left" valign="top" charoff="50">Diffuse large B-cell lymphoma</td></tr><tr><td align="left" valign="top" charoff="50">A1778G</td><td align="left" valign="top" charoff="50">D593G</td><td align="left" valign="top" charoff="50">Ileum</td><td align="left" valign="top" charoff="50">Diffuse large B-cell lymphoma</td></tr></tbody></table></table-wrap>, <xref ref-type="fig" rid="fig1">Figure 1</xref>). None of the corresponding normal samples showed evidence of mutations by SSCP (<xref ref-type="fig" rid="fig1">Figure 1</xref>), indicating the mutations detected in the specimens had risen somatically. We repeated the experiments two times, including tissue microdissection, PCR, SSCP and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).</p>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>Whereas the malignant melanoma is the most common tumour with <italic>BRAF</italic> mutations (roughly 60%), this tumour is known to possess a much lesser frequency of <italic>RAS</italic> mutations. Such differential occurrences of <italic>BRAF</italic> and <italic>RAS</italic> mutation in some human cancers led us to analyse <italic>BRAF</italic> mutation in NHL in which <italic>RAS</italic> mutation is known to be an uncommon event. We found that <italic>BRAF</italic> gene is somatically mutated in NHLs, indicating that RASâRAF kinase pathway in some NHLs may be regulated by somatic mutations of <italic>BRAF</italic>. Despite the low frequency of <italic>BRAF</italic> mutation in NHL compared with that of malignant melanoma, our data suggest that alteration of RASâRAF kinase pathway by <italic>BRAF</italic> mutation may play an important role in NHL carcinogenesis.</p>
      <p>In the present study, none of the <italic>BRAF</italic> mutations involved the amino acid V599. The data are quite contrast to those of malignant melanomas, where approximately 90% of <italic>BRAF</italic> mutations involved V599, raising the possibility that the contribution of <italic>BRAF</italic> mutations in the development of NHL might be different from that of malignant melanoma. Additionally, three (two G468A and one G468R) of the four <italic>BRAF</italic> mutations in this study involved the same amino acid (G468) that is located in the GXGXXG motif within the G-loop of the kinase domain. The G468A mutation was proven to be an activating mutation by the kinase assay and the transformation assay (<xref ref-type="other" rid="bib4">Davies <italic>et al</italic>, 2002</xref>). For G468R, a novel <italic>BRAF</italic> mutation, its functional implication is not known at this stage. In one NHL, we also found D593G <italic>BRAF</italic> mutation that has also been detected in colon tumours previously.</p>
      <p>The most impressive examples of recent cancer therapies used protein kinase inhibitors such as Imanitib (Gleevec) (<xref ref-type="other" rid="bib5">Downward, 2003</xref>). Since RASâRAFâMEKâERKâMAP kinase pathway is activated by protein kinase, therapies that target this signalling pathway would therefore be very valuable in treating tumours that have activating mutations of <italic>BRAF</italic>. In this respect, the present study may provide the possibility of therapy targeting mutated BRAF in NHL.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>This work was supported by the MRC funding from KOSEF through the Cell Death Disease Center at the Catholic University of Korea (R13-2002-005-01004-0).</p>
    </ack>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahuja</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Foti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bar-Eli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cline</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>The pattern of mutational involvement of <italic>RAS</italic> genes in human hematologic malignancies determined by DNA amplification and direct sequencing</article-title>
          <source>Blood</source>
          <year>1990</year>
          <volume>75</volume>
          <fpage>1684</fpage>
          <lpage>1690</lpage>
          <!--PubMed citation query: 'Blood||75|1684||bib1|'-->
          <pub-id pub-id-type="pmid">2183888</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bos</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title><italic>ras</italic> oncogenes in human cancer: a review</article-title>
          <source>Cancer Res</source>
          <year>1989</year>
          <volume>49</volume>
          <fpage>4682</fpage>
          <lpage>4689</lpage>
          <!--PubMed citation query: 'Cancer Res||49|4682||bib2|'-->
          <pub-id pub-id-type="pmid">2547513</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brose</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Volpe</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rishi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gerrero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Einhorn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Herlyn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Minna</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Albelda</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brignell</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>BRAF and RAS mutations in human lung cancer and melanoma</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>6997</fpage>
          <lpage>7000</lpage>
          <!--PubMed citation query: 'Cancer Res||62|6997||bib3|'-->
          <pub-id pub-id-type="pmid">12460918</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Teague</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woffendin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Garnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bottomley</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dicks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Floyd</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hawes</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kosmidou</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Menzies</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mould</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jayatilake</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gusterson</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hargrave</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maitland</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chenevix-Trench</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Riggins</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bigner</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cossu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flanagan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Seigler</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Darrow</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the BRAF gene in human cancer</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>417</volume>
          <fpage>949</fpage>
          <lpage>954</lpage>
          <!--PubMed citation query: 'Nature||417|949||bib4|'-->
          <pub-id pub-id-type="pmid">12068308</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Downward</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Targeting RAS signalling pathways in cancer therapy</article-title>
          <source>Nat Rev Cancer</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>11</fpage>
          <lpage>22</lpage>
          <!--PubMed citation query: 'Nat Rev Cancer||3|11||bib5|'-->
          <pub-id pub-id-type="pmid">12509763</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Cleary</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Delsol</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Wolf-Peeters</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Falini</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gatter</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Isaacson</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Knowles</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Muller-Hermelink</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Piris</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ralfkiaer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Warnke</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>84</volume>
          <fpage>1361</fpage>
          <lpage>1392</lpage>
          <!--PubMed citation query: 'Blood||84|1361||bib6|'-->
          <pub-id pub-id-type="pmid">8068936</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
          <article-title>A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections</article-title>
          <source>Virchows Arch</source>
          <year>1998</year>
          <volume>433</volume>
          <fpage>305</fpage>
          <lpage>309</lpage>
          <!--PubMed citation query: 'Virchows Arch||433|305||bib7|'-->
          <pub-id pub-id-type="pmid">9808431</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Sugarbaker</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Missense mutations of the <italic>BRAF</italic> gene in human lung adenocarcinoma</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>7001</fpage>
          <lpage>7003</lpage>
          <!--PubMed citation query: 'Cancer Res||62|7001||bib8|'-->
          <pub-id pub-id-type="pmid">12460919</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pollock</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>UL</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Yudt</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Hostetter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kakareka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Salem</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pohida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Heenan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duray</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Meltzer</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>High frequency of BRAF mutations in nevi</article-title>
          <source>Nat Genet</source>
          <year>2003</year>
          <volume>33</volume>
          <fpage>19</fpage>
          <lpage>20</lpage>
          <!--PubMed citation query: 'Nat Genet||33|19||bib9|'-->
          <pub-id pub-id-type="pmid">12447372</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajagopalan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bardelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lengauer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kinzler</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Vogelstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Velculescu</surname>
              <given-names>VE</given-names>
            </name>
          </person-group>
          <article-title>Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>418</volume>
          <fpage>934</fpage>
          <!--PubMed citation query: 'Nature||418|934||bib10|'-->
          <pub-id pub-id-type="pmid">12198537</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Satyamoorthy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gerrero</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Brose</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Volpe</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Van Belle</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elder</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Herlyn</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>756</fpage>
          <lpage>759</lpage>
          <!--PubMed citation query: 'Cancer Res||63|756||bib11|'-->
          <pub-id pub-id-type="pmid">12591721</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shin</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Pi</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma</article-title>
          <source>Am J Pathol</source>
          <year>1999</year>
          <volume>154</volume>
          <fpage>1785</fpage>
          <lpage>1791</lpage>
          <!--PubMed citation query: 'Am J Pathol||154|1785||bib12|'-->
          <pub-id pub-id-type="pmid">10362803</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuen</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Bignell</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsui</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Wooster</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>SY</given-names>
            </name>
          </person-group>
          <article-title>Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>6451</fpage>
          <lpage>6455</lpage>
          <!--PubMed citation query: 'Cancer Res||62|6451||bib13|'-->
          <pub-id pub-id-type="pmid">12438234</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>